



Biologics for Bone and Soft Tissue Regeneration: What Is New, What Is True

Guest Editors:

Dr. Ashim Gupta

South Texas Orthopaedic
Research Institute, Laredo, TX,
USA

Prof. Dr. Nicola Maffulli

Deadline for manuscript
submissions:

closed (31 July 2023)

Message from the Guest Editors

Injuries to the musculoskeletal system involve bone, ligaments, muscles, and tendons, producing pain, loss of function, instability, and, in the long term, osteoarthritis. Traditionally, the management of these injuries involves activity modification, physical therapy, a variety of surgical procedures, and pharmacological agents, including non-steroidal anti-inflammatory drugs, corticosteroids, viscosupplementation, and narcotics. All these modalities have limitations and potential side effects.

This collection highlights the current status, challenges, and emerging trends on the use of these biologic therapies for regenerating musculoskeletal tissues, including bone and soft tissues. We welcome both basic and translational original research, and review articles covering, but not limited to:

- mechanisms of action of therapeutic effects of these biologics
- therapeutics effects of these biologics in regenerating bone and/or soft tissue(s)
- comparison of these biologics to current standard treatments
- identifying research gaps to guide future research and streamline translation to clinical utilization





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)